A platform company
Linking pharmaceutical innovation and
commercialization with strong product
lifecycle management capability
commercialization with strong product
lifecycle management capability
Focusing on unmet clinical needs, we collaborate with global biotech/biopharma to jointly develop first- or best-in-class innovative products.
Adhering to the patient-centered philosophy, we are dedicated to providing competitive products and services that enable the more effective diagnosis and treatment, whilst enhancing clinical practice to the ultimate benefit of the patient.
On September 21, Shenzhen Enterprise Federation and Shenzhen Enterprise Directors Association released the list of “2022 Shenzhen Top 500 Enterprises”. With outstanding performance in terms of business scale, employees scale, tax payment, social responsibility, etc., Shenzhen Kangzhe Pharmaceutical Co., Ltd. (“Shenzhen Kangzhe”), a wholly-owned subsidiary of China Medical System Holdings Limited (“CMS” or the “Group”) was once again selected, ranking 130. As a local enterprise born and grown in Shenzhen, Shenzhen Kangzhe capitalizes on the global upstream and downstream resources accumulated by the Group to fulfill the mission of “Providing competitive products and services to meet unmet healthcare and aesthetic needs” and benefit more patients with accessible and affordable quality medicines. Being once again selected for the “Shenzhen Top 500 Enterprises” shows the recognition of Shenzhen Kangzhe’s comprehensive strength and brand value. In the future, CMS will continue to proactively seize the opportunities presented by the construction of the Guangdong-Hong Kong-Macao Greater Bay Area and the Pioneering Demonstration […]
We collaborate with global innovative companies in flexible structures to jointly build a pharmaceutical ecosystem in a sustainable and collaborative setting for the benefit of all stakeholders.
If you are interested in joining us, or curious about our business and products, please feel free to contact us.